Clik here to view.
ReNAgadeセラピューティクスが2023年のエンドポイント11に選出
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — RNA医薬品の無限の可能性を開拓するReNAgadeセラピューティクスは、この度、2023年のエンドポイント11企業の1社に選出されたことを発表しました。これはEndpoints News編集長のジョン・キャロル氏がバイオテクノロジー業界で最も有望な民間企業を表彰するものです。...
View ArticleClik here to view.
A*STAR’s Genome Institute of Singapore, NanoString and Next Level Genomics...
SINGAPORE A*STAR’s Genome Institute of Singapore (GIS), NanoString® Technologies, Inc. (NASDAQ: NSTG), and Next Level Genomics (NLG), today announced the establishment of a joint laboratory in...
View ArticleClik here to view.
Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD...
MADISON, Wis. Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer...
View ArticleClik here to view.
RoslinCT Boston任命Dean J. Morris为首席运营官
苏格兰爱丁堡和波士顿 (美国商业资讯)– RoslinCT是先进细胞和基因治疗领域领先的合同开发及制造组织（contract development and manufacturing organization，CDMO）。该公司欣然宣布任命Dean J....
View ArticleClik here to view.
ロズリンCTボストン、ディーン・J・モリスを最高業務責任者に任命
スコットランド、エディンバラ＆ボストン （ビジネスワイヤ） — 先端細胞・遺伝子治療薬の開発・受託製造機関（CDMO）の大手であるロズリンCTは、ボストン施設の最高業務責任者にディーン・J・モリスが就任したことを発表しました。同氏は、生物製剤・製薬・医療機器業界における商業生産業務や工程開発、エンジニアリング、臨床評価、品質管理業務において豊富な経験と専門知識を有しています。...
View ArticleClik here to view.
Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target...
SOUTH SAN FRANCISCO, Calif. Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and...
View ArticleClik here to view.
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory...
View ArticleClik here to view.
Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China
SUZHOU, China Gritgen Therapeutics Co., Ltd. (“Gritgen”), a biotechnology company focused on discovering and developing innovative gene therapy products, announces the successful validation and...
View ArticleClik here to view.
Immetas Therapeutics and GC Biopharma Announce Research Collaboration to...
EAST HANOVER, N.J. & YONGIN, South Korea Immetas Therapeutics and GC Biopharma today announced that they have entered into a research collaboration to discover and develop novel mRNA...
View ArticleClik here to view.
Immetas Therapeutics和GC Biopharma合作开发治疗炎症性疾病的mRNA药物
美国新泽西州东汉诺威和韩国龙仁 (美国商业资讯)– Immetas Therapeutics和GC Biopharma今天宣布，他们已经进入研究合作，双方正在将Immetas调节先天免疫的专有平台与GC Biopharma的mRNA与脂质纳米颗粒（LNP）递送平台相结合，开发用于广泛治疗炎症介导疾病的新型mRNA疗法。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
SEATTLE AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facility expansion for its new plasmid DNA...
View ArticleClik here to view.
AGCバイオロジクス、ハイデルベルクにてpDNAおよびmRNA製造ラインの増設を完了
シアトル （ビジネスワイヤ） — 世界大手のバイオ医薬品開発製造受託機関（CDMO）であるAGCバイオロジクスは、ドイツのハイデルベルクにある拠点において、新しいプラスミドDNA（pDNA）およびメッセンジャーRNA（mRNA）製造ラインの増設が完了したことを発表しました。...
View ArticleClik here to view.
Genome Insight, Inc. Announces Groundbreaking Research Collaboration with...
SAN DIEGO Genome Insight, Inc. and Shriners Children’s have launched a new human, whole-genome sequencing research project called Unraveling the Genetic Mysteries of Adolescent Idiopathic Scoliosis:...
View ArticleClik here to view.
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large,...
AUSTIN, Texas Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD)...
View ArticleClik here to view.
Genome Insight Announces Upcoming Presentations at 2023 NORD Breakthrough...
SAN DIEGO Genome Insight is set to unveil clinical research findings on the genetic foundation of rare diseases at the 2023 NORD Rare Disease & Orphan Products Breakthrough Summit (2023 NORD...
View ArticleClik here to view.
Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX...
TOKYO Skeletal muscle fibrosis which leads to locomotor dysfunction in Duchenne Muscular Dystrophy (DMD) could be significantly reduced by oral consumption of Neu-REFIX beta 1,3-1,6 glucans alone...
View ArticleClik here to view.
Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce...
CHICAGO Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced a significant move to transform global...
View ArticleClik here to view.
与日本东京国立精神·神经医疗研究中心医院的Yoshitsugu Aoki博士共同研究：Neu REFIX...
东京 (美国商业资讯)– 肌肉纤维化是杜兴氏肌肉营养不良症(DMD)导致运动功能障碍的原因之一，经过连续45天仅口服 Neu-REFIX beta 1,3-1,6 葡聚糖，不需任何其他药物，就能显著减轻DMD MDX小鼠模型中的肌肉纤维化。这项研究是与日本东京国立精神·神经医疗研究中心医院(NCNP)分子疗法部主任Yoshitsugu Aoki博士共同研究得到的。Yoshitsugu...
View ArticleClik here to view.
Clik here to view.
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity...
SAN DIEGO & SINGAPORE ImmunoScape, a biotechnology company focused on next-generation immunotherapies, published new peer-reviewed research that demonstrates the use of machine learning to...
View Article